{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-179062","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.052285+00:00","generated_at":"2026-05-15T03:56:22.223732+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA grants Breakthrough Therapy Designation to TERN-701; Merck acquisition mentioned in press release","bullets":["FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML-CP patients without T315I mutation, previously treated with 2+ TKIs.","Designation based on CARDINAL Phase 1/2 data: encouraging major molecular response and deep molecular response rates at week 24.","TERN-701 safety profile: majority of adverse events low grade; low severe adverse events and discontinuations.","Press release also notes recent agreement for Merck to acquire Terns (Nasdaq: TERN).","CEO Amy Burroughs cites BTD and Merck deal as potential acceleration to pivotal trial and patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179062","json":"https://secwatch.observer/filing/0001193125-26-179062.json","markdown":"https://secwatch.observer/filing/0001193125-26-179062.md","text":"https://secwatch.observer/filing/0001193125-26-179062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/0001193125-26-179062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/d122087d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:56:22.223732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068002","ticker":"REPL","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-022979","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-05-27T20:01:34+00:00","headline":"FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-022979","json":"https://secwatch.observer/filing/0001140361-26-022979.json","markdown":"https://secwatch.observer/filing/0001140361-26-022979.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/0001140361-26-022979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-061008","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-05-26T20:00:52+00:00","headline":"Spectral AI receives FDA De Novo clearance for DeepView System for burn indication","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061008","json":"https://secwatch.observer/filing/0001213900-26-061008.json","markdown":"https://secwatch.observer/filing/0001213900-26-061008.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026061008/0001213900-26-061008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026061008/ea0292182-8k_spectral.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}